Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefecon for Prevention of Relapse in IgA Nephropathy
NCT07604311Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Drug Delivery Systems, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nefecon in IgA nephropathy (IgAN) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Time to first composite disease relapse at 15 months. Started Jun 2026; status: recruiting.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07604311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604311.